Australia

Australia's modern psychedelic policy history is best understood as a pivot from prohibition toward restricted medical exceptions, not legalisation. The 2023 final scheduling decision created narrow Schedule 8 entries for MDMA and psilocybine while keeping broader Schedule 9 controls in place. The result is unusual internationally: psychiatrists can use the Authorised Prescriber pathway for two diagnoses, but there is still no ARTG-approved MDMA or psilocybine product. # # #

That policy change followed years of clinical-trial growth and medical advocacy. TGA's 2023 decision opened access from 1 July 2023, after earlier resistance to broader rescheduling because evidence, product quality and service delivery questions were still developing. The Office of Drug Control then became central to practical supply, since importation and manufacture need licence and permit controls. # #

Implementation has been deliberately conservative. Specialist psychiatrists need HREC support and TGA authorisation for each product, and patients must take MDMA or psilocybine under direct supervision in a clinical setting. The medicines cannot be taken home. DVA's 2025 funding settings made access more real for some veterans, but only after strict prior review and only through authorised providers. # # #

State and territory policy has moved at a different pace from federal therapeutic access. The ACT reduced penalties and added diversion routes for small personal quantities of selected drugs from 28 October 2023, including MDMA, LSD and psilocybine. That reform reduces criminal penalties in specific circumstances; it does not create lawful supply or a therapeutic market. #

Melbourne and Victoria are the centre of gravity for Australia's current psychedelic work. Monash provides the most visible academic anchor, with a public clinical-psychedelic-lab presence and active participant-facing information. Melbourne also hosts research and provider activity tied to treatment-resistant depression, functional neurological disorder and service design. # # # #

The regional strength is not only trial volume. Victoria combines psychiatry, neuroscience, hospital links, philanthropic interest and early service providers, which makes it a useful test bed for how psychedelic-assisted care might move from protocols to reproducible clinics. # #

Sydney remains the main counterweight. Its work around alcohol use disorder, PTSD, anorexia and palliative questions gives Australia a broader clinical profile than the MDMA/PTSD and psilocybine/TRD access rules alone suggest. # # #

For readers comparing countries, Australia's regional pattern is therefore concentrated but not closed: Melbourne is the densest node, Sydney is the second major node, and national access still depends on federal authorisation plus state or territory medicines controls. # #

The most likely near-term development is refinement of the Authorised Prescriber system, not broad legalisation. The December 2025 TGA consultation points to pressure for clearer psychiatrist, HREC, protocol and product expectations. Any loosening is likely to be incremental and focused on governance. # #

Reimbursement will decide whether access remains boutique. PBS listing gives esketamine a national subsidy route, but MDMA and psilocybine still rely on private payment, DVA eligibility or programme-specific insurance arrangements. Wider access would need stronger evidence, service-cost data and payer confidence. # # # # #

Australia is well placed to remain a regional research hub if universities, hospitals and authorised providers can align trial evidence with real-world delivery standards. The risk is a two-tier system where regulation permits access on paper but cost, workforce and geography keep treatment scarce. # # #